Current and future status of prostate cancer chemoprevention

Expert Review of Anticancer Therapy

Volumn 6, Issue 1, 2006, Pages 59-71

  Fujimoto, Naohiro ^a   Nomura, Masayoshi ^a   Matsumoto, Tetsuro ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Chemoprevention; Clinical trials; Mechanisms of action; Prostate cancer

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; BETA CAROTENE; CATECHIN; DUTASTERIDE; EFLORNITHINE; ETODOLAC; FINASTERIDE; FLAVONOID; ISOFLAVONE; ISOFLAVONOID; LIGNAN DERIVATIVE; LYCOPENE; NONSTEROID ANTIINFLAMMATORY AGENT; PHYTOESTROGEN; PRASTERONE; RALOXIFENE; RETINOID; RETINOL; RETINOL PALMITATE; ROFECOXIB; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SELENIUM; SHORT CHAIN FATTY ACID; SOYBEAN PROTEIN; STEROID 5ALPHA REDUCTASE INHIBITOR; SULINDAC SULFONE; TOREMIFENE; UNINDEXED DRUG; VITAMIN D; ARACHIDONIC ACID;

ACUTE HEART INFARCTION; AFRICAN AMERICAN; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; CALORIC RESTRICTION; CANCER INCIDENCE; CANCER PREVENTION; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DIETARY INTAKE; DRUG EFFICACY; DRUG POTENCY; EARLY DIAGNOSIS; ENVIRONMENTAL FACTOR; GENETIC RISK; HIGH RISK PATIENT; HISTOPATHOLOGY; HISTORY; HUMAN; JAPAN; MALE; NONHUMAN; ORCHIECTOMY; PHYSICAL ACTIVITY; PROSTATE CANCER; RACE DIFFERENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEXUAL DYSFUNCTION; SHORT COURSE THERAPY; SKIN CANCER; SURVIVAL TIME; TREATMENT OUTCOME; PHYSIOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION;

ANTIOXIDANTS; ARACHIDONIC ACID; CHEMOPREVENTION; CLINICAL TRIALS; HUMANS; MALE; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 33644840623     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.1.59     Document Type: Review

References (126)

1. Shimizu H, Ross RK, Yatani R, Henderson BE, Mack TM. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br. J. Cancer 63(6), 12-18 (1991).
2. Liebarman R. Androgen deprivation therapy for prostate cancer chemoprevention: current status and future directions for agent development. Urology 58(Suppl.2A), 83-90 (2001).
3. Greenwald P, Kelloff GJ. The role of chemoprevention in cancer control. In: Principles of Chemoprevention. IARC Scientific Publication No 139. Lyon, France. 13-22 (1996).
4. Lieberman R. Evolving strategies for prostate cancer chemoprevention trials. World J. Urol. 21(1), 3-8 (2003).
5. O'Shaughnessy JA, Kelloff GJ, Gordon GB et al. Treatment and prevention of IEN: an important target for accelerated new agent development. Clin. Cancer Res. 8(2), 314-346 (2002).
6. Bastian PJ, Yegnasubramanian S, Palapattu GS et al. Molecular biomarker in prostate cancer: the role of CpG island hypermethylation. Eur. Urol. 46(6), 698-708 (2004).
7. Bastian PJ, Palapattu GS, Yegnasubramanian S et al. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin. Cancer Res. 11(11), 4037-4043 (2005).
8. Thomas LN, Douglas RC, Vessey JP et al. 5α-Reductase Type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. J. Urol. 170(5), 2019-2025 (2003).
9. Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. World J. Urol. 19(6), 413-425 (2002).
10. Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349(3), 215-224 (2003).
11. Thompson IM, Klein EA, Lippman SM, Coltman CA, Djavan B. Prevention of prostate cancer with finasteride: US/European perspective. Eur. Urol. 44(6), 650-655 (2003).
12. Civantos F, Soloway MS, Pinto JE. Histopathological effects of androgen deprivation in prostatic cancer. Semin. Urol. Oncol. 14(2 Suppl.2), 22-31 (1996).
13. Bostwick DG. Prostatic adenocarcinoma following androgen deprivation therapy: the new difficulty in histologic interpretation. Anat. Pathol. 3, 1-16 (1998).
14. Reuter VE. Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology. 49(Suppl.3A), 16-22 (1997).
15. Ishikawa S, Soloway MS, Van der Zwaag R et al. Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. J. Urol. 141(5), 1139-1142 (1989).
16. Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? J. Urol. 163(3), 824-827, (2000).
17. Schatzl G, Madersbacher S, Haitel A et al. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer. J. Urol. 169(4), 1312-1315 (2003).
18. Iczkowski KA, Qiu J, Qian J et al. The dual 5-α-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. Urology. 65(1), 76-82 (2005).
19. Lotan Y, Cadeddu JA, Lee JJ et al. Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes. J. Clin. Oncol. 23(9), 1911-1920 (2005).
20. Andriole G, Bostwick D, Brawley O et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J. Urol. 172(4Pt 1), 1314-1317 (2004).
21. Shibata Y, Ito K, Suzuki K et al. Changes in the endocrine environment of the human prostate transition zone with aging: simultaneous quantitative analysis of prostatic sex steroids and comparison with human prostatic histological composition. Prostate 42(1), 25-55 (2000).
22. Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B. Serum testosterone levels in healthy young black and white men. J. Natl Cancer Inst. 76(1), 45-48 (1986).
23. Moore RJ, Gazak JM, Wilson JD. Regulation of cytoplasmic dihydrotestosterone binding in dog prostate by 17α-estradiol. J. Clin. Investig. 63(3), 351-357 (1979).
24. Mobbs BG, Johnson IE, Connolly JG, Thompson J. Concentration and cellular distribution of androgen receptor in human prostatic neoplasia: can estrogen treatment increase androgen receptor content? J. Steroid Biochem. 19(3), 1279-1290 (1983).
25. Blanchere M, Berthaut I, Portois MC, Mestayer C, Mowszowicz I. Hormonal regulation of the androgen receptor expression in human prostatic cells in culture. J. Steroid Biochem. Mol. Biol. 66(5), 319-326 (1998).
26. Leav I, Ho SM, Ofner P, Merk FB, Kwan PW, Damassa D. Biochemical alterations in sex hormone-induced hyperplasia and dysplasia of the dorsolateral prostates of Noble rats. J. Natl Cancer Inst. 80(13), 1045-1053 (1988).
27. Leav I, Merk FB, Kwan PW, Ho SM. Androgen-supported estrogen-enhanced epithelial proliferation in the prostates of intact Noble rats. Prostate 15(1), 23-40 (1989).
28. Ofner P, Bosland MC, Vena RL. Differential effects of diethylstilbesterol and estradiol-17 α in combination with testosterone on rat prostate lobes. Toxicol. Appl. Pharmacol. 112(2), 300-309 (1992).
29. Lau K, Leav I, Ho SM. Rat estrogen receptor-e and -f and progesterone receptor mRNA expression in various prostatic lobes and microdissected normal and dysplastic epithelial tissues of the Noble rats. Endocrinology 139(1), 524-427 (1998).
30. Ho SM, Lee KF, Lane K. Neoplastic transformation of the prostate. In: Prostate: Basic and Clinical Aspects. Naz RK (Ed.). CRC Press, NY, USA. 74-114 (1997).
31. Waters DJ, Bostwick DG. The canine prostate is a spontaneous model of intraepithelial neoplasia and prostate cancer progression. AntiCancer Res. 17(3A), 1467-1470 (1997).
32. Thrasher LB. Prostate cancer: causes, risk factors and prevention. In: New frontiers in the diagnosis and treatment of prostatic diseases. Golden: Medical Education Collaborative 8-19 (1999).
33. Messina M, Barnes S. The role of soy products in reducing risk of cancer. J. Natl Cancer Inst. 83(8), 541-546 (1991).
34. Denis L, Morton MS, Griffiths K. Diet and its preventive role in prostatic disease. Eur. Urol. 35(5-6), 377-387 (1999).
35. Sonoda T, Nagata Y, Mori M et al. A case-control study of diet and prostate cancer in Japan: possible protective effect of traditional Japanese diet. Cancer Sci. 95(3), 238-242 (2004).
36. Holzbeierlein JM, McIntosh J, Thrasher JB. The role of soy phytoestrogens in prostate cancer. Curr. Opin. Urol. 15(1), 17-22 (2005).
37. Bemis DL, Capodice JL, Desai M, Buttyan R, Katz AE. A concentrated aglycone isoflavone preparation (GCP) that demonstrates potent antiprostate cancer activity in vitro and in vivo. Clin. Cancer Res. 10(15), 5282-5292 (2004).
38. Jarred RA, Keikha M, Dowling C et al. Induction of apoptosis in low to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones. Cancer Epidemiol. Biomarkers Prev. (12), 1689-1696 (2002).
39. Raghow S, Hooshdaran MZ, Katiyar S, Steiner MS. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res. 62(5), 1370-1376 (2002).
40. Steiner MS. Role of peptide growth factors in the prostate: a review. Urology. 42(1), 99-110 (1993).
41. Steiner MS. Review of peptide growth factors in benign prostatic hyperplasia and urological malignancy. J. Urol. 153(4), 1085-1096 (1995).
42. Lam HY. Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase. Biochem. Biophys. Res. Commun. 118(1), 27-32 (1984).
43. Rohlff C, Blagosklonny MV, Kyle E et al. Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21(waf1/cip1). Prostate 37(1), 51-59 (1998).
44. Steiner MS, Pound CR. Phase IIA clinical trial to test the efficacy and safety of Toremifene in men with high-grade prostatic intraepithelial neoplasia. Clin. Prostate Cancer 2(1), 24-31 (2003).
45. Price D, Stein B, Goluboff E et al. Double-blind, placebo-controlled trial of toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia. J. Clin. Oncol. 23(16S, Part 1), 41th ASCO Annual Meeting (Abstract 1003).
46. Kim IY, Kim BC, Seong do H et al. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Res. 62(18), 5365-5369 (2002).
47. Halliwell B. Free radicals, anti-oxidants, and human disease: curiosity, cause, or consequence? Lancet 344(8924), 721-724 (1994).
48. Toledano MB, Leonard WJ. Modulation of transcription factor NF-κ B binding activity by oxidation-reduction in vitro. Proc. Natl. Acad. Sci. USA 88(10), 4328-4332 (1991).
49. Wei H. Activation of oncogenes and/or inactivation of anti-oncogenes by reactive oxygen species. Med. Hypotheses. 39(3), 267-270 (1992).
50. Hainaut P, Milner J. Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res. 53(19), 4469-4473 (1993).
51. Nakamura A, Shirai T, Takahashi S, Ogawa K, Hirose M, Ito N. Lack of modification by naturally occurring anti-oxidants of 3,2′-dimethyl-4-aminobiphenyl-initiated rat prostate Carcinogenesis. Cancer Lett. 58(3), 241-246 (1991).
52. Webber MM, Perez-Ripoll EA, James GT. Inhibitory effects of selenium on the growth of DU-145 human prostate carcinoma cells in vitro. Biochem. Biophys. Res. Commun. 130(2), 603-609 (1985).
53. Ip C, Medina D. Current concept of selenium and mammary tumorigenesis. In: Cellular and molecular biology of breast cancer. Plenum Press, NY, USA, 479 (1987).
54. Kiremidjian-Schumacher L, Stotzky G. Selenium and immune responses. Environ. Res. 42(2), 277-303 (1987).
55. Thompson HJ, Wilson A, Lu J et al. Comparison of the effects of an organic and an inorganic form of selenium on a mammary carcinoma cell line. Carcinogenesis 15(2), 183-186 (1994).
56. Redman C, Scott JA, Baines AT et al. Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines. Cancer Lett. 125(1-2), 103-110 (1998).
57. Shimada T, El-Bayoumy K, Upadhyaya P, Sutter TR, Guengerich FP, Yamazaki H. Inhibition of human cytochrome P450-catalyzed oxidations of xenobiotics and procarcinogens by synthetic organoselenium compounds. Cancer Res. 57(21), 4757-4764 (1997).
58. El-Bayoumy K. The role of selenium in cancer prevention. In: Practice of oncology. Lippincott., PA, USA. 1-15 (1991).
59. Bedwal RS, Nair N, Sharma MP, Mathur RS. Selenium-its biological perspectives. Med. Hypotheses. 41(2), 150-159 (1993).
60. Day NE, Bingham SA. Re: Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J. Natl Cancer Inst. 86(21), 1645-1648 (1994).
61. Li JY, Taylor PR, Li B et al. Nutrition intervention trials in Linxian, China: multiple vitamin/mineral supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia. J. Natl Cancer Inst. 85(18), 1492-1498 (1993).
62. Yoshizawa K, Willett WC, Morris SJ et al., Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J. Natl Cancer Inst. 90(16), 1219-1224 (1998).
63. Li H, Stampfer MJ, Giovannucci EL et al. A prospective study of plasma selenium levels and prostate cancer risk. J. Natl Cancer Inst. 96(9), 696-703 (2004).
64. Clark LC, Combs GF Jr, Turnbull BW et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276(24), 1957-1963 (1996).
65. Burton GW, Foster DO, Perly B, Slater TF, Smith IC, Ingold KU. Biological antioxidants. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 311(1152), 565-578 (1985).
66. Fieshner NE, Kucuk O. Anti-oxidant dietary supplements: rationale and current status as chemopreventive agents for prostate cancer. Urology 57(Suppl.4A), 90-94. (2001).
67. Mahoney CW, Azzi A. Vitamin E inhibits protein kinase C activity. Biochem. Biophys. Res. Commun. 29, 154(2), 694-697 (1988).
68. Chatelain E, Boscoboinik DO, Bartoli GM et al. Inhibition of smooth muscle cell proliferation and protein kinase C activity by tocopherols and tocotrienols. Biochim. Biophys. Acta. 1176(1-2), 83-89 (1993).
69. Wang W, Higuchi CM. Induction of NAD(P)H: quinone reductase by vitamins A, E and C in Colo205 colon cancer cells. Cancer Lett. 98(1), 63-69 (1995).
70. Traber MG, Packer L. Vitamin E: beyond anti-oxidant function. Am. J. Clin. Nutr. 62(Suppl.6), 1501S-1509S (1995).
71. Hsing AW, Comstock GW, Abbey H, Polk BF. Serologic precursors of cancer. Retinol, carotenoids, and tocopherol and risk of prostate cancer. J. Natl Cancer Inst. 82(11), 941-946 (1990).
72. Hartman TJ, Albanes D, Rautalahti M et al. Physical activity and prostate cancer in the α-Tocopherol, β-Carotene (ATBC) Cancer Prevention Study (Finland). Cancer Causes Control 9(1), 11-18 (1998).
73. Virtamo J, Pietinen P, Huttunen JK et al. Incidence of cancer and mortality following α-tocopherol and β-carotene supplementation: a postintervention follow-up. JAMA 290(4), 476-485 (2003).
74. Jiang Q, Wong J, Fyrst H, Saba JD, Ames BN. γ-Tocopherol or combinations of vitamin E forms induce cell death in human prostate cancer cells by interrupting sphingolipid synthesis. Proc. Natl Acad Sci. USA 101(51), 17825-17830 (2004).
75. Klein EA, Thompson IM, Lippman SM et al. SELECT: the next prostate cancer prevention trial. Selenum and Vitamin E Cancer Prevention Trial. J. Urol. 166(4), 1311-1315 (2001).
76. Stahl W, Nicolai S, Briviba K et al. Biological activities of natural and synthetic carotenoids: induction of gap junctional communication and singlet oxygen quenching. Carcinogenesis 18(1), 89-92 (1997).
77. Hantz HL, Young LF, Martin KR. Physiologically attainable concentrations of lycopene induce mitochondrial apoptosis in LNCaP human prostate cancer cells. Exp. Biol. Med. 30(3), 171-179 (2005).
78. Amir H, Karas M, Giat J et al. Lycopene and 1,25-dihydroxyvitamin D3 co-operate in the inhibition of cell cycle progression and induction of differentiation in HL-60 leukemic cells. Nutr. Cancer 33(1), 105-12 (1999).
79. Aust O, Ale-Agha N, Zhang L, Wollersen H, Sies H, Stahl W. Lycopene oxidation product enhances gap junctional communication. Food Chem. Toxicol. 41(10), 1399-1407 (2003).
80. Mills PK, Beeson WL, Phillips RL, Fraser GE. Cohort study of diet, lifestyle, and prostate cancer in Adventist men. Cancer 64(3), 598-604 (1989).
81. Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Intake of carotenoids and retinol in relation to risk of prostate cancer. J. Natl Cancer Inst. 87(23), 1767-1776 (1995).
82. Giovannucci E, Rimm EB, Liu Y, Stampfer MJ, Willett WC. A prospective study of tomato products, lycopene, and prostate cancer risk. J. Natl Cancer Inst. 94(5), 391-398 (2002).
83. Jian L, Du CJ, Lee AH, Binns CW. Do dietary lycopene and other carotenoids protect against prostate cancer? Int. J. Cancer. 113(6), 1010-1014 (2005).
84. Gann PH, Ma J, Giovannucci E et al. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res. 59(6), 1225-1230 (1999).
85. Ansari MS, Gupta NP. A comparison of lycopene and orchidectomy vs. orchidectomy alone in the management of advanced prostate cancer. BJU. Int. BJU. Int. 94(4) 678 (2004).
86. Cooper R, Morre DJ, Morre DM. Medical benefits of green tea: part 2. Review of anticancer properties. J. Altern. Complement Med. 11(4), 639-652 (2005).
87. Caporiali A, Davalli P, Astancolle S et al. The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin overexpression. Carcinogenesis 25(11), 2217-2224 (2004).
88. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins (GTCs) in high grade PIN subjects: a preliminary report from a 1 year proof of principle study. 96th Annual Meeting, American Association for Cancer Research (2005) (Abstract 4400).
89. Kirschenbaum A, Liu X, Yao S, Levine AC. The role of cyclooxygenase-2 in prostate cancer. Urology 58 (2 Suppl. 1), 127-131 (2001).
90. Kamijo T, Sato T, Nagatomi Y, Kitamura T. Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines. Int. Urol. 8(7), S35-S39 (2001).
91. Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J. Urol. 164(3 Pt. 1), 820-825 (2000).
92. Gupta S, Adhami VM, Subbarayan M et al. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res. 64(9), 3334-4333 (2004).
93. Reddy BS, Hirose Y, Luber R et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res. 60(2), 293-297 (2000).
94. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 58(3), 409-412 (1998).
95. Pruthi RS, Derksen JE, Moore D. A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. BJU Int. 93(3), 275-278 (2004).
96. Piazza GA, Alberts DS, Hixon LJ et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res. 57(14), 2909-2915 (1997).
97. Lim JT, Piazza GA, Han EK et al. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem. Pharmacol. 58(7), 1097-1107 (1999).
98. Goluboff ET, Shabsigh A, Saidi JA et al. Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. Urology 53(2), 440-445 (1999).
99. Thompson WJ, Piazza GA, Li H et al. Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated f-catenin. Cancer Res. 60(13), 3338-3342 (2000).
100. Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann. Intern. Med. 142(7), 481-489 (2005).
101. Solomon DH, Schneeweiss S, Glynn RJ et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 109(17), 2068-2073 (2004).
102. Kimmel SE, Berlin JA, Reilly M et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann. Intern. Med. 164(3), 142-157 (2005).
103. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenese-2. N. Engl J. Med. 345(6), 433-442 (2001).
104. Rao KV, Johnson WD, Bosland MC et al. Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone. Cancer Res. 59(13), 3084-3089 (1999).
105. Ciolino HP, Yeh GC. The steroid hormone dehydroepiandrosterone inhibits CYP1A1 expression in vitro by a post-transcriptional mechanism. J. Biol. Chem. 274(49), 35186-35190 (1999).
106. Trump DL. Retinoids in bladder, testis and prostate cancer: epidemiologic, preclinical and clinical observations. Leukemia 8 (Suppl.3), S50-S54 (1994).
107. Peehl DM, Wong ST, Stamey TA. Vitamin A regulates proliferation and differentiation of human prostatic epithelial cells. Prostate 23(1), 69-78 (1993).
108. Omenn GS, Goodman GE, Thornquist MD et al. Risk factors for lung cancer and for intervention effects in CARET, the β-Caroten and Retinol Efficacy Trial. J. Natl Cancer Inst. 88(21), 1550-1559 (1996).
109. Peehl DM, Krishnan AV, Feldman D. Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer. J. Nutr. 133(Suppl.7), 2461s-2469s (2003).
110. Kirshnan AV, Peehl DM, Feldman D. The role of vitamin D in prostate cancer. Recent Results. Cancer Res. 164, 205-221 (2003).
111. Feldman D. Androgen and vitamin D receptor gene polymorphisms: the long and short of prostate cancer risk. J. Natl Cancer Inst. 89(2), 109-111 (1997).
112. Ingles SA, Coetzee GA, Ross RK et al. Association of prostate cancer with vitamin D receptor haplotypes in African-Americans. Cancer Res. 58(8), 1620-1623 (1998).
113. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with prostate cancer. JAMA 281(15), 1395-1400 (1999).
114. Gross C, Stamey T, Hancock S, Feldman D. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J. Urol. 159(6), 2035-2039 (1998).
115. Heston WD, Kadmon D, Lazan DW, Fair WR. Copenhagen rat prostatic tumor ornithine decarboxylase activity (ODC) and the effect of the CDC inhibitor α-difluoromethylornithine. Prostate 3(4), 383-389 (1982).
116. Samid D, Shack S, Myers CE. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J. Clin. Invest. 91(5), 2288-2295 (1993).
117. Pineau T, Hudgins WR, Liu L et al. Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs. Biochem. Pharmacol. 52(4), 659-667 (1996).
118. Carducci MA, Gilbert J, Bowling MK et al. A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin. Cancer Res. 7(10), 3047-3055 (2001).
119. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med. 142(1), 37-46 (2005).
120. The effect of vitamin E and β carotene on the incidence of lung cancer and other cancers in male smokers. The α-Tocopherol, β Carotene Cancer Prevention Study Group. N. Engl J. Med. 330(15), 1029-1035 (1994).
121. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Nat. Cancer Inst. 90(18), 1371-1388 (1998).
122. Kim J, Sun P, Lam Y et al. Changes in serum proteomic patterns by presurgical α-tocopherol and L-senenomethionine supplementation in prostate cancer. Cancer Epidemiol. Biomarkers Prev. 14(7), 1698-1702 (2005).
123. Nelson WG. Agents in development for prostate cancer prevention. Expert. Opin. Investig. Drugs 13(12), 1541-1554 (2004).
124. Lucia MS, Torkko KC. Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale. J. Urol. 171(Suppl.), S30-S35 (2004).
125. Platz EA, Marzo AM. Epidemiology of inflammation and prostate cancer. J. Urol. 171(Suppl.), S36-S40 (2004).
126. Palapattu GS, Sutcliffe S, Bastian PJ et al. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 26(7), 1170-1181 (2005).